Client News

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Darwin AG launches commercialization of Multi-Cancer Check—a blood test for early detection of 13 types of cancer

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting

NVision and Aarhus University Awarded Innovation Fund Denmark Grant to Advance Clinical Translation of Quantum-Enhanced MRI

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation

InflaRx to Report Full Year 2025 Results on March 19, 2026

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference